Effect of LAF237 on Glucagon Secretion in Patients With Type 2 Diabetes and in Healthy Subjects

Exclusion Criteria

• •A history of:
• •Type 1 diabetes, diabetes that is a result of pancreatic injury, or secondary forms of diabetes, e.g., Cushing's syndrome and acromegaly
• •Acute metabolic diabetic complications (such as ketoacidosis or hyperosmolar state (coma)) within the past 6 months
• •Torsades de Pointes, ventricular tachycardia or ventricular fibrillation
• •Any severe hypoglycemic episode within 3 months of screening
• •Use of any of the following medications:
• •Antihypertensive or lipid-lowering agents unless on a stable dose for at least 3 months prior to screening
• •Chronic insulin treatment (\> 4 weeks of treatment in the absence of an intercurrent illness) within the past 6 months
• •Chronic oral/intramuscular/intravenous corticosteroid treatment ( \> 7 consecutive days of treatment) within 8 weeks prior to screening
• •First degree relative of an individual with T2DM
• •History of gestational diabetes
• •Use of any prescription medication within 1 month prior to dosing. Use of over-the-counter medications or vitamins within 14 days prior to dosing.